Volume 30, No 6, Jun 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 6, June 2020: 507-519   |  Open Access

REVIEW ARTICLE

The future of cancer immunotherapy: microenvironment-targeting combinations

Yonina R. Murciano-Goroff¹ , Allison Betof Warner^1,2,3,4 , Jedd D. Wolchok^1,2,3,4,*

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
²Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
³Weill Cornell Medicine, New York, NY 10065, USA
⁴Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
^†These authors contributed equally: Yonina R. Murciano-Goroff, Allison Betof Warner
Correspondence: Jedd D. Wolchok(wolchokj@mskcc.org)

Immunotherapy holds the potential to induce durable responses, but only a minority of patients currently respond. The etiologies of primary and secondary resistance to immunotherapy are multifaceted, deriving not only from tumor intrinsic factors, but also from the complex interplay between cancer and its microenvironment. In addressing frontiers in clinical immunotherapy, we describe two categories of approaches to the design of novel drugs and combination therapies: the first involves direct modification of the tumor, while the second indirectly enhances immunogenicity through alteration of the microenvironment. By systematically addressing the factors that mediate resistance, we are able to identify mechanistically-driven novel approaches to improve immunotherapy outcomes.

https://doi.org/10.1038/s41422-020-0337-2

FULL TEXT | PDF

Browse 608